panel-8-gene-editing-and-advanced-therapies
21 May 2026VideosAmericasDavid Longmuir, Philip Ormonde Fitzpatrick | Danielle Burns, Philip Ormonde Fitzpatrick | Scott Douglas, Editas | Nicole Mastrangelo, The Broad Institute of MIT and Harvard

WATCH: Gene editing and advanced therapies—patent strategies for the next generation of precision medicine

The rapid evolution of CRISPR and base editing brings transformative medical potential alongside deeply complex IP and licensing hurdles. This session explores how companies can balance innovation with risk mitigation in a crowded and highly contested precision medicine landscape.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
6 November 2026   Uncertainty over whether a patent can be challenged through inter partes review at the USPTO has only increased since the discretionary denial policy was introduced, so how should companies plan? Mauricio Uribe and Maria Anderson of Davis Wright Tremaine explain.
Americas
17 June 2026   A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.
Americas
15 June 2026   Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.